Recruitment of APPL1 to ubiquitin-rich aggresomes in response to proteasomal impairment

Experimental Cell Research

Volumn 317, Issue 8, 2011, Pages 1093-1107

  Pilecka, Iwona ^a   Sadowski, Lukasz ^a   Kalaidzidis, Yannis ^b   Miaczynska, Marta ^a  

^a INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

^b MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS   (Germany)

Author keywords

Aggresome; APPL1; Endosome; Proteasome; Ubiquitination

Indexed keywords

ADAPTOR PROTEIN; CELL PROTEIN; LYSINE; PROTEIN APPL1; PROTEOME; UBIQUITIN; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG; VIMENTIN;

AGGRESOME; ARTICLE; CELL STRESS; CONTROLLED STUDY; ENDOSOME; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SOLUBILIZATION; UBIQUITINATION;

EID: 79953069853     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.02.002     Document Type: Article

References (44)

1. Jovic M., Sharma M., Rahajeng J., Caplan S. The early endosome: a busy sorting station for proteins at the crossroads. Histol. Histopathol. 2010, 25:99-112.
2. Miaczynska M., Christoforidis S., Giner A., Shevchenko A., Uttenweiler-Joseph S., Habermann B., Wilm M., Parton R.G., Zerial M. APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. Cell 2004, 116:445-456.
3. Zoncu R., Perera R.M., Balkin D.M., Pirruccello M., Toomre D., De Camilli P. A phosphoinositide switch controls the maturation and signaling properties of APPL endosomes. Cell 2009, 136:1110-1121.
4. Acconcia F., Sigismund S., Polo S. Ubiquitin in trafficking: the network at work. Exp. Cell Res. 2009, 315:1610-1618.
5. Melikova M.S., Kondratov K.A., Kornilova E.S. Two different stages of epidermal growth factor (EGF) receptor endocytosis are sensitive to free ubiquitin depletion produced by proteasome inhibitor MG132. Cell Biol. Int. 2006, 30:31-43.
6. Longva K.E., Blystad F.D., Stang E., Larsen A.M., Johannessen L.E., Madshus I.H. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J. Cell Biol. 2002, 156:843-854.
7. Melman L., Geuze H.J., Li Y., McCormick L.M., Van Kerkhof P., Strous G.J., Schwartz A.L., Bu G. Proteasome regulates the delivery of LDL receptor-related protein into the degradation pathway. Mol. Biol. Cell 2002, 13:3325-3335.
8. van Kerkhof P., Alves dos Santos C.M., Sachse M., Klumperman J., Bu G., Strous G.J. Proteasome inhibitors block a late step in lysosomal transport of selected membrane but not soluble proteins. Mol. Biol. Cell 2001, 12:2556-2566.
9. Levkowitz G., Waterman H., Zamir E., Kam Z., Oved S., Langdon W.Y., Beguinot L., Geiger B., Yarden Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 1998, 12:3663-3674.
10. Mori S., Tanaka K., Omura S., Saito Y. Degradation process of ligand-stimulated platelet-derived growth factor beta-receptor involves ubiquitin-proteasome proteolytic pathway. J. Biol. Chem. 1995, 270:29447-29452.
11. Jeffers M., Taylor G.A., Weidner K.M., Omura S., Vande Woude G.F. Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway. Mol. Cell. Biol. 1997, 17:799-808.
12. Yu A., Malek T.R. The proteasome regulates receptor-mediated endocytosis of interleukin-2. J. Biol. Chem. 2001, 276:381-385.
13. Schenck A., Goto-Silva L., Collinet C., Rhinn M., Giner A., Habermann B., Brand M., Zerial M. The endosomal protein App l1 mediates Akt substrate specificity and cell survival in vertebrate development. Cell 2008, 133:486-497.
14. Deepa S.S., Dong L.Q. APPL1: role in adiponectin signaling and beyond. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E22-E36.
15. Rashid S., Pilecka I., Torun A., Olchowik M., Bielinska B., Miaczynska M. Endosomal adaptor proteins APPL1 and APPL2 are novel activators of beta-catenin/TCF-mediated transcription. J. Biol. Chem. 2009, 284:18115-18128.
16. Banach-Orlowska M., Pilecka I., Torun A., Pyrzynska B., Miaczynska M. Functional characterization of the interactions between endosomal adaptor protein APPL1 and the NuRD co-repressor complex. Biochem. J. 2009, 423:389-400.
17. Han Y.H., Moon H.J., You B.R., Park W.H. The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH. Oncol. Rep. 2009, 22:215-221.
18. Wojcik C., Schroeter D., Wilk S., Lamprecht J., Paweletz N. Ubiquitin-mediated proteolysis centers in HeLa cells: indication from studies of an inhibitor of the chymotrypsin-like activity of the proteasome. Eur. J. Cell Biol. 1996, 71:311-318.
19. Johnston J.A., Ward C.L., Kopito R.R. Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 1998, 143:1883-1898.
20. Garcia-Mata R., Gao Y.S., Sztul E. Hassles with taking out the garbage: aggravating aggresomes. Traffic 2002, 3:388-396.
21. Kopito R.R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 2000, 10:524-530.
22. Wong E.S., Tan J.M., Soong W.E., Hussein K., Nukina N., Dawson V.L., Dawson T.M., Cuervo A.M., Lim K.L. Autophagy-mediated clearance of aggresomes is not a universal phenomenon. Hum. Mol. Genet. 2008, 17:2570-2582.
23. Lim K.L., Chew K.C., Tan J.M., Wang C., Chung K.K., Zhang Y., Tanaka Y., Smith W., Engelender S., Ross C.A., Dawson V.L., Dawson T.M. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J. Neurosci. 2005, 25:2002-2009.
24. Magnifico A., Ettenberg S., Yang C., Mariano J., Tiwari S., Fang S., Lipkowitz S., Weissman A.M. WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation. J. Biol. Chem. 2003, 278:43169-43177.
25. Confalonieri S., Salcini A.E., Puri C., Tacchetti C., Di Fiore P.P. Tyrosine phosphorylation of Eps15 is required for ligand-regulated, but not constitutive, endocytosis. J. Cell Biol. 2000, 150:905-912.
26. protocol, Calcium phosphate-mediated transfection of eukaryotic cells, Nature Methods 2 (2005) 319-320.
27. Collinet C., Stoter M., Bradshaw C.R., Samusik N., Rink J.C., Kenski D., Habermann B., Buchholz F., Henschel R., Mueller M.S., Nagel W.E., Fava E., Kalaidzidis Y., Zerial M. Systems survey of endocytosis by multiparametric image analysis. Nature 2010, 464:243-249.
28. Rink J., Ghigo E., Kalaidzidis Y., Zerial M. Rab conversion as a mechanism of progression from early to late endosomes. Cell 2005, 122:735-749.
29. Curran M.P., McKeage K. Bortezomib: a review of its use in patients with multiple myeloma. Drugs 2009, 69:859-888.
30. Suh K.S., Goy A. Bortezomib in mantle cell lymphoma. Future Oncol. 2008, 4:149-168.
31. Fortun J., Dunn W.A., Joy S., Li J., Notterpek L. Emerging role for autophagy in the removal of aggresomes in Schwann cells. J. Neurosci. 2003, 23:10672-10680.
32. Muqit M.M., Abou-Sleiman P.M., Saurin A.T., Harvey K., Gandhi S., Deas E., Eaton S., Payne Smith M.D., Venner K., Matilla A., Healy D.G., Gilks W.P., Lees A.J., Holton J., Revesz T., Parker P.J., Harvey R.J., Wood N.W., Latchman D.S. Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J. Neurochem. 2006, 98:156-169.
33. Garcia-Mata R., Bebok Z., Sorscher E.J., Sztul E.S. Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J. Cell Biol. 1999, 146:1239-1254.
34. Regan-Klapisz E., Sorokina I., Voortman J., de Keizer P., Roovers R.C., Verheesen P., Urbe S., Fallon L., Fon E.A., Verkleij A., Benmerah A., van Bergen en Henegouwen P.M. Ubiquilin recruits Eps15 into ubiquitin-rich cytoplasmic aggregates via a UIM-UBL interaction. J. Cell Sci. 2005, 118:4437-4450.
35. Heir R., Ablasou C., Dumontier E., Elliott M., Fagotto-Kaufmann C., Bedford F.K. The UBL domain of PLIC-1 regulates aggresome formation. EMBO Rep. 2006, 7:1252-1258.
36. Olzmann J.A., Chin L.S. Parkin-mediated K63-linked polyubiquitination: a signal for targeting misfolded proteins to the aggresome-autophagy pathway. Autophagy 2008, 4:85-87.
37. Chen C., Matesic L.E. The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev. 2007, 26:587-604.
38. Nawrocki S.T., Carew J.S., Maclean K.H., Courage J.F., Huang P., Houghton J.A., Cleveland J.L., Giles F.J., McConkey D.J. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 2008, 112:2917-2926.
39. Markossian K.A., Kurganov B.I. Protein folding, misfolding, and aggregation. Formation of inclusion bodies and aggresomes. Biochem. Mosc 2004, 69:971-984.
40. Lim K.L., Dawson V.L., Dawson T.M. Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases?. Neurobiol. Aging 2006, 27:524-529.
41. Ciechanover A., Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003, 40:427-446.
42. Rajkumar S.V., Richardson P.G., Hideshima T., Anderson K.C. Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 2005, 23:630-639.
43. Zavrski I., Jakob C., Schmid P., Krebbel H., Kaiser M., Fleissner C., Rosche M., Possinger K., Sezer O. Proteasome: an emerging target for cancer therapy. Anticancer Drugs 2005, 16:475-481.
44. Nencioni A., Grunebach F., Patrone F., Ballestrero A., Brossart P. The proteasome and its inhibitors in immune regulation and immune disorders. Crit. Rev. Immunol. 2006, 26:487-498.